ERYTECH PHARMA (ERYP.PA) Stock Price & Overview
EPA:ERYP • FR0011471135
Current stock price
The current stock price of ERYP.PA is 0.801 EUR. Today ERYP.PA is up by 0.25%. In the past month the price decreased by -8.56%. In the past year, price decreased by -28.23%.
ERYP.PA Key Statistics
- Market Cap
- 24.844M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.56
- Dividend Yield
- N/A
ERYP.PA Stock Performance
ERYP.PA Stock Chart
ERYP.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ERYP.PA. When comparing the yearly performance of all stocks, ERYP.PA is a bad performer in the overall market: 91.52% of all stocks are doing better.
ERYP.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERYP.PA. While ERYP.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ERYP.PA Earnings
ERYP.PA Forecast & Estimates
9 analysts have analysed ERYP.PA and the average price target is 3.67 EUR. This implies a price increase of 358.43% is expected in the next year compared to the current price of 0.801.
For the next year, analysts expect an EPS growth of 22.35% and a revenue growth 16.44% for ERYP.PA
ERYP.PA Groups
Sector & Classification
ERYP.PA Financial Highlights
Over the last trailing twelve months ERYP.PA reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 99.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.44 |
ERYP.PA Ownership
ERYP.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 26.79 | 40.049B | ||
| 1AE | ARGENX SE | 26.69 | 39.987B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.44B | ||
| 2X1 | ABIVAX SA | N/A | 8.044B | ||
| ABVX | ABIVAX SA | N/A | 8.028B | ||
| GXE | GALAPAGOS NV | N/A | 1.691B | ||
| GLPG | GALAPAGOS NV | N/A | 1.687B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 1.012B | ||
| PHGN | PHARMING GROUP NV | 41.99 | 1.011B | ||
| PHARM | PHARMING GROUP NV | 41.23 | 1.005B | ||
| 6IV | INVENTIVA SA | N/A | 981.43M | ||
| IVA | INVENTIVA SA | N/A | 980.391M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ERYP.PA
Company Profile
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Company Info
IPO: 2013-05-07
ERYTECH PHARMA
60 avenue Rockefeller, Batiment Adenine
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 49
Phone: 33478744438.0
ERYTECH PHARMA / ERYP.PA FAQ
What does ERYTECH PHARMA do?
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
What is the current price of ERYP stock?
The current stock price of ERYP.PA is 0.801 EUR. The price increased by 0.25% in the last trading session.
Does ERYP stock pay dividends?
ERYP.PA does not pay a dividend.
What is the ChartMill rating of ERYTECH PHARMA stock?
ERYP.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ERYTECH PHARMA?
ERYTECH PHARMA (ERYP.PA) currently has 49 employees.
Can you provide the ownership details for ERYP stock?
You can find the ownership structure of ERYTECH PHARMA (ERYP.PA) on the Ownership tab.